Viridian Therapeutics, Inc./DE Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Viridian Therapeutics, Inc./DE (VRDN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $729.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $496.00K.
- Viridian Therapeutics, Inc./DE right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $729.00K, a 46.98% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $496.00K.
- Viridian Therapeutics, Inc./DE right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00.
- Viridian Therapeutics, Inc./DE right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $729.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $729.00K 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $496.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $496.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |